Market Intelligence, Clinical Progress, and High-Purity Reagents for Activin B Pathway Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for INHBB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | INHBB Recombinant Homodimer Protein HEK293 Expressed (Native Glycosylation), Sequence Verified, High Purity (>95%), Endotoxin <1 EU/µg, Theoretical MW ~50kDa. |
View INHBB Products |
| Gene Delivery | INHBB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. |
View INHBB Products |
| Benchmark Ab | Anti-INHBB Neutralizing Reference Antibody Recombinant positive control for binding and blockade assays. |
View INHBB Products |
| Validator | INHBB siRNA Set Sequence-verified. For knockdown and specificity verification. |
View INHBB Products |
| Related Target A | INHBA (Activin A Subunit) Synergistic TGF-beta superfamily partner; validates activin pathway blockade. |
View INHBA Products |
| Related Target B | ACVR2B (Activin Receptor Type IIB) Shared type II receptor hub for activin B and myostatin signaling. |
View ACVR2B Products |
| Related Target C | FST (Follistatin) Natural antagonist; Essential for competition assays. |
View FST Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno INHBB ortholog proteins available with >95% purity, Sequence Verified |
| Subfamily selectivity (vs INHBA) | INHBA/INHBB homolog panel strictly verified by mass spec for counter-screening |
| Native Dimeric Conformation | HEK293 Expressed (Native Glycosylation), precisely folded dimers; >95% dimer content by SEC-HPLC |
| Lack of Controls | Research-grade neutralizing reference antibody and Follistatin included |
| False Positives / Specificity | Sequence-verified siRNA included for target-specificity checks |
Live INHBB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for INHBB therapeutics is intensifying, with major players shifting focus from broad activin pathway inhibitors to INHBB-selective biologics. As first-generation ACVR2B-targeted agents demonstrate clinical proof-of-concept in muscle and metabolic disease, the next wave of R&D is targeting ligand-level selectivity to disentangle activin B from myostatin and activin A biology. While the broader ActRII pathway (targeting INHBA, INHBB, GDF11 collectively) has seen major investment with pan-ActRII fusion proteins like Sotatercept (Merck) entering the clinic for anemia and pulmonary hypertension, specific INHBB (Activin B) inhibition represents the next frontier for tissue-selective therapeutic intervention. Current preclinical efforts focus on discriminating Activin B-specific signaling from Activin A-driven toxicities, particularly in erythropoiesis suppression and muscle wasting indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Discovery-stage biologics pipelines | Cachexia, Muscle Wasting, Metabolic Disease | Ligand-binding Inhibition (Need high-purity INHBB antigen for SPR/BLI) |
| Ligand Trap / Decoy | TGF-beta pathway engineering groups | Fibrosis, Anemia | Selectivity Profiling (Need INHBA/INHBB homolog panel for counter-screening) |
| siRNA / Gene Therapy | Academic translational programs | Oncology, Rare Disease | Knockdown Validation (Need potent siRNA and ORF lentivirus rescue controls) |
| Bi-specific (INHBB/INHBA) | Novartis, Roche (preclinical) | Cancer Cachexia | Heterodimer Validation (Need both INHBB and INHBA proteins) |
Molecular Differentiation & Assay Strategy
To develop a best-in-class INHBB therapeutic, differentiation is required across several dimensions:
Affinity
Circulating Activin B is a soluble ligand; high affinity (pM range) is typically needed for full neutralization. However, moderate affinity may offer a better safety window. Assay needs: SPR/BLI kinetics and cell-based SMAD3 reporter assays.
Selectivity
This is the biggest differentiation barrier. INHBB shares high homology with INHBA and GDF8, and cross-reactivity could lead to unintended hematopoietic suppression or uncontrolled muscle hypertrophy. Counter-screening must use a panel of INHBA, GDF8, and other homologs. TarMart provides HEK293-expressed INHBB with native glycosylation and a full homolog panel for selectivity profiling.
Delivery
Subcutaneous injection is preferred for chronic metabolic diseases. High-concentration formulations (>100 mg/mL) require assessment of viscosity and phase separation. TarMart's high-purity, low-aggregation INHBB antigen supports early formulation compatibility screening.
Mechanism
INHBB is a soluble cytokine; core mechanism is ligand neutralization and receptor blockade. Key assays include INHBB-ACVR2B/ALK4 competition binding and cell surface receptor occupancy analysis.
Epitope
Ideal epitopes should target regions with maximal sequence divergence from INHBA, particularly in the mature domain beta-sheet region exposed after proprotein cleavage, to ensure no cross-reactivity.
TarMart's reagent design supports these assays:
- HEK293 expression ensures correct human glycosylation and disulfide bonding (INHBB functions as a dimer), maintaining native conformational epitopes.
- High-purity protein (>95%, endotoxin <1 EU/µg, mass spec verified) is ready for SPR/BLI and crystallography.
- Homolog panel (INHBA, GDF8, ACVR2B) enables rapid off-target risk assessment.
- Gene tools (siRNA, ORF lentivirus) support target engagement and rescue experiments.